[go: up one dir, main page]

DK0810870T3 - Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf - Google Patents

Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf

Info

Publication number
DK0810870T3
DK0810870T3 DK95914792T DK95914792T DK0810870T3 DK 0810870 T3 DK0810870 T3 DK 0810870T3 DK 95914792 T DK95914792 T DK 95914792T DK 95914792 T DK95914792 T DK 95914792T DK 0810870 T3 DK0810870 T3 DK 0810870T3
Authority
DK
Denmark
Prior art keywords
tumor rejection
rejection antigen
antigen precursor
derived tumor
complexes
Prior art date
Application number
DK95914792T
Other languages
Danish (da)
English (en)
Inventor
Cornelis J M Melief
M W Visseren
W M Kast
Der Bruggen Pierre Van
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Leiden filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK0810870T3 publication Critical patent/DK0810870T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95914792T 1994-03-24 1995-03-21 Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf DK0810870T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
PCT/US1995/003535 WO1995025530A1 (en) 1994-03-24 1995-03-21 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof

Publications (1)

Publication Number Publication Date
DK0810870T3 true DK0810870T3 (da) 2001-07-23

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95914792T DK0810870T3 (da) 1994-03-24 1995-03-21 Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf

Country Status (17)

Country Link
US (3) US5554724A (xx)
EP (1) EP0810870B1 (xx)
JP (1) JP3360137B2 (xx)
CN (1) CN1149257A (xx)
AT (1) ATE201214T1 (xx)
AU (1) AU682597B2 (xx)
CA (1) CA2186006A1 (xx)
DE (1) DE69520959T2 (xx)
DK (1) DK0810870T3 (xx)
ES (1) ES2158943T3 (xx)
FI (1) FI963780L (xx)
GR (1) GR3036320T3 (xx)
NO (1) NO963918L (xx)
NZ (2) NZ329695A (xx)
PT (1) PT810870E (xx)
WO (1) WO1995025530A1 (xx)
ZA (1) ZA952375B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
AU740222C (en) * 1996-03-20 2002-10-10 Genzyme Corporation A method for identifying cytotoxic T-cell epitopes
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
AU732468B2 (en) 1997-06-23 2001-04-26 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
ID27162A (id) * 1998-07-28 2001-03-08 Kyogo Itoh Cs Peptida antigen tumor yang dibatasi hla-a2 yang berasal dari sart-1
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
SI1620456T1 (sl) 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
DE602004032365D1 (de) * 2003-10-08 2011-06-01 Sanofi Pasteur Inc Modifizierter cea/b7-vektor
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
KR20140016315A (ko) 2011-03-07 2014-02-07 크리에이티브 네일 디자인 인코포레이티드 Uv-경화성 미용 손톱 코팅제를 위한 조성물 및 방법
WO2013137953A1 (en) 2012-03-15 2013-09-19 Exxonmobil Chemical Patents Inc. Oxygen tailoring of polyethylene
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE69334076D1 (de) * 1992-08-07 2006-11-30 Pharmexa Inc Hla bindepeptide und ihre verwendungen
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Also Published As

Publication number Publication date
ATE201214T1 (de) 2001-06-15
WO1995025530A1 (en) 1995-09-28
GR3036320T3 (en) 2001-11-30
US6063900A (en) 2000-05-16
US5554724A (en) 1996-09-10
EP0810870B1 (en) 2001-05-16
NO963918L (no) 1996-11-20
NZ329695A (en) 2000-05-26
NZ283561A (en) 1998-04-27
CA2186006A1 (en) 1995-09-28
FI963780A0 (fi) 1996-09-23
US6147187A (en) 2000-11-14
DE69520959D1 (de) 2001-06-21
EP0810870A1 (en) 1997-12-10
JPH10502329A (ja) 1998-03-03
NO963918D0 (no) 1996-09-19
EP0810870A4 (en) 1998-11-25
AU682597B2 (en) 1997-10-09
PT810870E (pt) 2001-09-28
ES2158943T3 (es) 2001-09-16
JP3360137B2 (ja) 2002-12-24
AU2189395A (en) 1995-10-09
DE69520959T2 (de) 2002-03-28
FI963780L (fi) 1996-09-23
CN1149257A (zh) 1997-05-07
ZA952375B (en) 1995-12-15

Similar Documents

Publication Publication Date Title
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
ATE447585T1 (de) Antigener komplex, der ein immunstimulierendes peptid enthält, cd4 und chemokinrezeptor-domäne zur behandlung von hiv und immunerkrankungen
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
ATE403680T1 (de) Herstellung tetravalenter antikörper
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
EA200702202A1 (ru) Идентификация представленных hla-a2 т-клеточных эпитопов, полученных из раково-эмбрионального антиген-незрелого рецепторного белка ламинила, и их применение
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung
GB9826143D0 (en) Tumour rejection antigens
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
Nguyen et al. Recognition of breast cancer‐associated peptides by tumor‐reactive, HLA‐class I restricted allogeneic cytotoxic T lymphocytes
PT996636E (pt) Antigenio ha-1
ATE207757T1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
Cinar Development of mutation-specific T-cell receptor gene therapy for treatment of B-cell malignancies
Myeloma-Reactive et al. Targeting Positive Regulatory Domain
ITMI20042227A1 (it) Peptide in grado di rompere il complesso m-p53-p63, m-p53-p73 e m-p53-relative proteine isoformi formatosi nelle cellule tumorali e relativi impieghi in campo farmacologico